المؤلفون: Annamaria Zimmermann, Gosuke Homma, Relay investigators, Kazuhiko Nakagawa, Bente Frimodt-Moller, Makoto Nishio, Carla Visseren-Grul, Sotaro Enatsu, Jin-Yuan Shih, Edward B. Garon, Chao-Hua Chiu, Takashi Seto, Martin Reck, Keunchil Park, Kiyotaka Yoh, Fumio Imamura

المصدر: Cancer Science

مصطلحات موضوعية: 0301 basic medicine, Oncology, Cancer Research, medicine.medical_specialty, ramucirumab, Population, Placebo, Ramucirumab, 03 medical and health sciences, 0302 clinical medicine, Clinical Research, Internal medicine, medicine, Clinical endpoint, Lung cancer, Erlotinib Hydrochloride, education, East Asia, non‐small‐cell lung cancer, education.field_of_study, business.industry, erlotinib hydrochloride, Hazard ratio, General Medicine, Original Articles, medicine.disease, 030104 developmental biology, 030220 oncology & carcinogenesis, Original Article, Erlotinib, business, epidermal growth factor receptor, medicine.drug

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b88552886e3f322e461d4b3d204ae5ab
http://europepmc.org/articles/PMC7734014

المؤلفون: Carla Visseren-Grul, Santiago Ponce Aix, Shinji Atagi, Annamaria Zimmermann, Edward B. Garon, Kiyotaka Yoh, Katherine B. Winfree, Bente Frimodt-Moller, Relay investigators, Kazuhiko Nakagawa, Denis Moro-Sibilot, Martin Reck

المصدر: Current Medical Research and Opinion. 36:1667-1675

مصطلحات موضوعية: Oncology, medicine.medical_specialty, business.industry, General Medicine, 030204 cardiovascular system & hematology, medicine.disease, Placebo, respiratory tract diseases, Ramucirumab, 03 medical and health sciences, 0302 clinical medicine, Egfr mutation, Internal medicine, medicine, heterocyclic compounds, In patient, 030212 general & internal medicine, Erlotinib, Non small cell, Lung cancer, business, neoplasms, medicine.drug

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::295aadcfab6981ab7e817976e3794b61
https://doi.org/10.1080/03007995.2020.1808781

المؤلفون: Carla Visseren-Grul, Relay investigators, Kazuhiko Nakagawa, Bente Frimodt-Moller, S. Ponce Aix, E. Nadal, E. Fabre, Martin Reck, Denis Moro-Sibilot, Silvia Novello, M. Alonso Garcia, Edward B. Garon, Annamaria Zimmermann

المصدر: Cancer Treatment and Research Communications, Vol 27, Iss, Pp 100378-(2021)

مصطلحات موضوعية: Male, Oncology, Cancer Research, Lung Neoplasms, Placebos, 0302 clinical medicine, Carcinoma, Non-Small-Cell Lung, Antineoplastic Combined Chemotherapy Protocols, Ethnicity, Medicine, 030212 general & internal medicine, Epidermal growth factor receptor, RC254-282, Aged, 80 and over, education.field_of_study, biology, Brain Neoplasms, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Middle Aged, Progression-Free Survival, ErbB Receptors, Europe, Survival Rate, 030220 oncology & carcinogenesis, Hypertension, Female, Drug Eruptions, Erlotinib, medicine.drug, Adult, Subset Analysis, medicine.medical_specialty, Population, Antibodies, Monoclonal, Humanized, Placebo, Ramucirumab, Erlotinib Hydrochloride, Young Adult, 03 medical and health sciences, Phase III, Double-Blind Method, Internal medicine, Humans, education, Lung cancer, Response Evaluation Criteria in Solid Tumors, Aged, business.industry, medicine.disease, Regional subset, United States, Mutation, biology.protein, Vascular endothelial growth factor, business, Progressive disease

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ff3bc54f9f8402e2820ce4233a0e3957
http://www.sciencedirect.com/science/article/pii/S2468294221000769

لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل.